uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $37.82.

QURE has been the subject of several recent analyst reports. Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of uniQure in a research report on Thursday, May 29th. Chardan Capital reissued a "buy" rating and issued a $38.00 price objective on shares of uniQure in a research note on Friday, May 30th. Wall Street Zen lowered uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Finally, Cantor Fitzgerald raised uniQure to a "strong-buy" rating in a research note on Monday, May 19th.

uniQure Trading Up 2.1%

NASDAQ:QURE opened at $14.28 on Thursday. The stock has a market cap of $782.26 million, a price-to-earnings ratio of -3.25 and a beta of 0.08. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 11.99. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The business has a fifty day moving average of $14.53 and a 200-day moving average of $14.00.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.25. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. Equities analysts predict that uniQure will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other news, Director David D. Meek sold 2,112 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director owned 34,190 shares in the company, valued at $494,045.50. The trade was a 5.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rachelle Suzanne Jacques sold 2,112 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director directly owned 28,346 shares of the company's stock, valued at $409,599.70. This represents a 6.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock worth $322,426 in the last three months. Insiders own 4.79% of the company's stock.

Institutional Trading of uniQure

Several large investors have recently added to or reduced their stakes in QURE. Oppenheimer & Co. Inc. acquired a new stake in shares of uniQure in the fourth quarter worth $320,000. Raymond James Financial Inc. purchased a new stake in uniQure in the 4th quarter worth about $1,951,000. Monaco Asset Management SAM acquired a new stake in uniQure during the 4th quarter worth about $2,414,000. Twin Tree Management LP purchased a new position in uniQure during the 4th quarter valued at about $77,000. Finally, JPMorgan Chase & Co. grew its stake in uniQure by 14.7% during the 4th quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company's stock valued at $8,014,000 after acquiring an additional 58,246 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.